Maxim Group initiated coverage on shares of scPharmaceuticals (NASDAQ:SCPH – Get Rating) in a research note published on Tuesday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $10.00 price target on the stock.
Several other brokerages have also issued reports on SCPH. SVB Leerink increased their target price on shares of scPharmaceuticals to $6.00 and gave the stock a market perform rating in a research note on Tuesday, May 17th. HC Wainwright reissued a buy rating and set a $15.00 target price on shares of scPharmaceuticals in a research note on Wednesday, July 13th.
scPharmaceuticals Trading Up 1.8 %
NASDAQ:SCPH opened at $5.11 on Tuesday. The firm’s fifty day moving average is $4.88 and its 200-day moving average is $4.99. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.81 and a current ratio of 4.81. scPharmaceuticals has a 52 week low of $3.48 and a 52 week high of $7.24. The firm has a market cap of $139.87 million, a P/E ratio of -4.87 and a beta of 0.39.
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of SCPH. Sandy Cove Advisors LLC purchased a new stake in shares of scPharmaceuticals in the fourth quarter valued at about $53,000. Envestnet Asset Management Inc. raised its holdings in shares of scPharmaceuticals by 20.4% in the fourth quarter. Envestnet Asset Management Inc. now owns 12,882 shares of the company’s stock valued at $65,000 after purchasing an additional 2,186 shares during the last quarter. IPG Investment Advisors LLC purchased a new stake in shares of scPharmaceuticals in the fourth quarter valued at about $72,000. Commonwealth Equity Services LLC purchased a new stake in shares of scPharmaceuticals in the second quarter valued at about $74,000. Finally, Simplex Trading LLC raised its holdings in shares of scPharmaceuticals by 2,366.0% in the first quarter. Simplex Trading LLC now owns 23,156 shares of the company’s stock valued at $131,000 after purchasing an additional 22,217 shares during the last quarter. Institutional investors and hedge funds own 72.84% of the company’s stock.
scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure.
- Get a free copy of the StockNews.com research report on scPharmaceuticals (SCPH)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
Receive News & Ratings for scPharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for scPharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.